GlobeNewswire Inc.··NaAtea Pharma's Hepatitis C Combo Shows Drug-Interaction Promise at EASL
Atea Pharmaceuticals presented Phase 1 data showing its bemnifosbuvir/ruzasvir combination has minimal drug-drug interactions, supporting best-in-class potential for hepatitis C treatment.
AVIRPhase 3 trialsAT-587